| Kara Kennemore, MFT, LPPC | |
|
3820 Auburn Blvd, Sacramento, CA 95821-2124 | |
| (916) 300-6576 | |
| Not Available |
| Full Name | Kara Kennemore |
|---|---|
| Gender | Female |
| Speciality | Marriage & Family Therapist |
| Location | 3820 Auburn Blvd, Sacramento, California |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1487439873 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 103TC1900X | Psychologist - Counseling | (* (Not Available)) | Secondary |
| 106H00000X | Marriage & Family Therapist | (* (Not Available)) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Kara Kennemore, MFT, LPPC 9444 Harbour Point Dr Apt 151, Elk Grove, CA 95758-3733 Ph: (916) 597-4159 | Kara Kennemore, MFT, LPPC 3820 Auburn Blvd, Sacramento, CA 95821-2124 Ph: (916) 300-6576 |
News Archive
Clues that point toward new risk mechanisms for developing Parkinson's disease are hiding in some unusual spots, according to a study published today in Scientific Reports
Tafamidis meglumine was approved in November 2011 for the treatment of transthyretin amyloidosis in adults. This rare disorder is caused by a defective gene and is associated with progressive nerve damage (neurological degeneration) that tafamidis is supposed to delay.
OPKO Health, Inc. today announced that it has entered into a collaboration agreement with Bristol-Myers Squibb Company relating to OPKO's new diagnostic test technology. OPKO's simple blood tests are being developed, based on its proprietary platform technology, to identify biomarkers for a wide variety of diseases including neurodegenerative disorders and various malignancies.
BioLife Solutions, Inc., a leading developer, manufacturer, and marketer of biopreservation tools for cells, tissues, and organs, and OriGen Biomedical, a leading provider of biologic packaging products for research and clinical blood and cell-based therapies, today announced that the companies will introduce sterile standard and custom biologic packaging products pre-filled with BioLife's serum-free, protein-free HypoThermosol® cell and tissue storage/transport media and CryoStor™ cryopreservation media.
AstraZeneca's new oral syk inhibitor, fostamatinib (R788), recently in-licensed from Rigel Pharmaceuticals, Inc., significantly improved outcomes of patients with rheumatoid arthritis who responded inadequately to ongoing treatment with methotrexate, according to phase II study data published in The New England Journal of Medicine today.
› Verified 5 days ago